Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide

Colloids and Surfaces B: Biointerfaces

Volumn 135, Issue , 2015, Pages 717-725

  d'Angelo, Ivana ^a   Casciaro, Bruno ^b   Miro, Agnese ^c   Quaglia, Fabiana ^c   Mangoni, Maria Luisa ^b   Ungaro, Francesca ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antimicrobial peptide; Biofilm; Cystic fibrosis; Nanoparticles; PLGA; Pseudomonas aeruginosa; Pulmonary delivery

Indexed keywords

BACTERIA; BIOFILMS; BODY FLUIDS; EMULSIFICATION; MICROORGANISMS; NANOPARTICLES; PATIENT TREATMENT; PEPTIDES; POLYPEPTIDES; POLYVINYL ALCOHOLS;

ANTIMICROBIAL PEPTIDE; CYSTIC FIBROSIS; PLGA; PSEUDOMONAS AERUGINOSA; PULMONARY DELIVERY;

BIOLOGICAL ORGANS;

CATIONIC ANTIMICROBIAL PEPTIDE; COLISTIN; LACTOSE; MANNITOL; MUCIN; NANOPARTICLE; POLYGLACTIN; POLYPEPTIDE ANTIBIOTIC AGENT; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CATION; DRUG CARRIER; PEPTIDE;

AEROSOL; ARTICLE; BIOFILM; CONTROLLED STUDY; CYSTIC FIBROSIS; DIFFUSION; DRUG EFFICACY; DRUG STABILITY; DRUG TRANSPORT; DRY POWDER; EMULSION; LUNG INFECTION; MUCUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SOLVENT DIFFUSION; SPRAY DRYING; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; COMPLICATION; HUMAN; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; CATIONS; CYSTIC FIBROSIS; DRUG CARRIERS; HUMANS; NANOPARTICLES; PEPTIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84940489686     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.08.027     Document Type: Article

References (41)

1. Cipolla D., Chan H.K. Inhaled antibiotics to treat lung infection. Pharm. Pat. Anal. 2013, 2:647-663.
2. Gaspar M.C., Couet W., Olivier J.C., Pais A.A., Sousa J.J. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32:1231-1252.
3. Weers J. Inhaled antimicrobial therapy - barriers to effective treatment. Adv. Drug Deliv. Rev. 2014, 10.
4. Amin R., Ratjen F. Emerging drugs for cystic fibrosis. Expert Opin. Emerg. Drugs 2014, 19:143-155.
5. Michalopoulos A.S. Aerosolized antibiotics: the past, present and future, with a special emphasis on inhaled colistin. Expert Opin. Drug Deliv. 2012, 9:493-495.
6. Batoni G., Maisetta G., Brancatisano F.L., Esin S., Campa M. Use of antimicrobial peptides against microbial biofilms: advantages and limits. Curr. Med. Chem. 2011, 18:256-279.
7. Uttley L., Harnan S., Cantrell A., Taylor C., Walshaw M., Brownlee K., Tappenden P. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis. Eur. Respir. Rev. 2013, 22:476-486.
8. Hadinoto K., Cheow W.S. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa. Colloids Surf. B 2014, 116:772-785.
9. Ungaro F., D'Angelo I., Miro A., La Rotonda M.I., Quaglia F. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J. Pharm. Pharmacol. 2012, 64:1217-1235.
10. D'Angelo I., Conte C., La Rotonda M.I., Miro A., Quaglia F., Ungaro F. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv. Drug Deliv. Rev. 2014, 75:92-111.
11. D'Angelo I., Conte C., Miro A., Quaglia F., Ungaro F. Pulmonary drug delivery: a role for polymeric nanoparticles?. Curr. Top. Med. Chem. 2015, 15:386-400.
12. Forier K., Messiaen A.S., Raemdonck K., Deschout H., Rejman J., De B.F., Nelis H., De Smedt S.C., Demeester J., Coenye T., Braeckmans K. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomed. (Lond.) 2013, 8:935-949.
13. Forier K., Messiaen A.S., Raemdonck K., Nelis H., De S.S., Demeester J., Coenye T., Braeckmans K. Probing the size limit for nanomedicine penetration into Burkholderia multivorans and Pseudomonas aeruginosa biofilms. J. Controlled Release 2014, 195:21-28.
14. Ensign L.M., Schneider C., Suk J.S., Cone R., Hanes J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv. Mater. 2012, 24:3887-3894.
15. Water J.J., Smart S., Franzyk H., Foged C., Nielsen H.M. Nanoparticle-mediated delivery of the antimicrobial peptide plectasin against Staphylococcus aureus in infected epithelial cells. Eur. J. Pharm. Biopharm. 2015.
16. Ungaro F., D'Angelo I., Coletta C., d'Emmanuele di Villa Bianca R., Sorrentino R., Perfetto B., Tufano M.A., Miro A., La Rotonda M.I., Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Controlled Release 2012, 157:149-159.
17. D'Angelo I., Parajo Y., Horvath A., Keri G., La Rotonda M.I., Alonso M.J. Improved delivery of angiogenesis inhibitors from PLGA: poloxamer blend micro- and nano-particles. J. Microencapsulation 2010, 27:57-66.
18. Maiolino S., Moret F., Conte C., Fraix A., Ungaro F., Sortino S., Reddi E., Quaglia F. Hyaluronan-decorated polymer nanoparticles targeting CD44 receptor for the combined photo/chemo-therapy of cancer. Nanoscale 2015, 7:5643-5653.
19. Moss O.R. Simulants of lung interstitial fluid. Health Phys. 1979, 36:447-448.
20. Ibrahim B.M., Park S., Han B., Yeo Y. A strategy to deliver genes to cystic fibrosis lungs: a battle with environment. J. Controlled Release 2011, 155:289-295.
21. Ungaro F., Giovino C., Coletta C., Sorrentino R., Miro A., Quaglia F. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur. J. Pharm. Sci. 2010, 41:60-70.
22. Ceri H., Olson M., Morck D., Storey D., Read R., Buret A., Olson B. The MBEC assay system: multiple equivalent biofilms for antibiotic and biocide susceptibility testing. Methods Enzymol. 2001, 337:377-385.
23. Falciani C., Lozzi L., Pollini S., Luca V., Carnicelli V., Brunetti J., Lelli B., Bindi S., Scali S., Di G.A., Rossolini G.M., Mangoni M.L., Bracci L., Pini A. Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. PLoS One 2012, 7:e46259.
24. Luca V., Stringaro A., Colone M., Pini A., Mangoni M.L. Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell. Mol. Life Sci. 2013, 70:2773-2786.
25. Vogel H.J., Bonner D.M. Acetylornithinase of E. coli: partial purification and some properties. J. Biol. Chem. 1956, 218:97-106.
26. Mah T.F., Pitts B., Pellock B., Walker G.C., Stewart P.S., O'Toole G.A. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003, 20(426):306-310.
27. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
28. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:598-603.
29. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,l-lactide-co-glycolide) and its derivatives. J. Controlled Release 2008, 125:193-209.
30. Du A.W., Stenzel M.H. Drug carriers for the delivery of therapeutic peptides. Biomacromolecules 2014, 15:1097-1114.
31. Greally P., Whitaker P., Peckham D. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Med. Res. Opin. 2012, 28:1059-1067.
32. Yang M., Lai S.K., Yu T., Wang Y.Y., Happe C., Zhong W., Zhang M., Anonuevo A., Fridley C., Hung A., Fu J., Hanes J. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J. Controlled Release 2014, 192:202-208.
33. Wang Y.Y., Lai S.K., So C., Schneider C., Cone R., Hanes J. Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One 2011, 6:e21547.
34. Tomoda K., Ohkoshi T., Nakajima T., Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf. B 2008, 64:70-76.
35. Tomoda K., Ohkoshi T., Kawai Y., Nishiwaki M., Nakajima T., Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf. B 2008, 61:138-144.
36. Jensen D.K., Jensen L.B., Koocheki S., Bengtson L., Cun D., Nielsen H.M., Foged C. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J. Controlled Release 2012, 157:141-148.
37. Wills P.J. Inhaled mannitol in cystic fibrosis. Expert Opin. Invest. Drugs 2007, 16:1121-1126.
38. Hoiby N., Ciofu O., Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 2010, 5:1663-1674.
39. Rybtke M.T., Jensen P.O., Hoiby N., Givskov M., Tolker-Nielsen T., Bjarnsholt T. The implication of Pseudomonas aeruginosa biofilms in infections. Inflamm. Allergy Drug Targets 2011, 10:141-157.
40. Oglesby-Sherrouse A.G., Djapgne L., Nguyen A.T., Vasil A.I., Vasil M.L. The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa. Pathog. Dis. 2014, 70:307-320.
41. Mohamed A.F., Cars O., Friberg L.E. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. J. Antimicrob. Chemother. 2014, 69:1350-1361.